The OROV genome sequences are available from the Genbank database (accession numbers MK506818 - MK506832). The metagenomic sequencing data are available from the Sequence Read Archive database as fastq files (accession numbers SAMN12241859 - SAMN12241881).

Introduction {#sec001}
============

Oropouche virus (OROV) is the causative agent of Oropouche fever, an arboviral illness that is usually self-limiting and mild but in rare cases infects the central nervous system and causes meningitis \[[@pntd.0007897.ref001],[@pntd.0007897.ref002]\]. The virus belongs to the genus *Orthobunyavirus*, family *Peribunyaviridae*, and has a negative-sense, single-stranded RNA genome composed of three segments. The small (S) segment (0.95 kb) encodes the nucleoprotein (N) and non-structural protein (NSs), the medium (M) segment (4.36 kb) encodes a polyprotein consisting of two glycoproteins (Gn, Gc) and one non-structural protein (NSm), whilst the large (L) segment (6.85 kb) encodes the RNA dependent RNA polymerase (RdRP) \[[@pntd.0007897.ref003]\].

OROV is one of the most clinically important orthobunyaviruses in the Americas, with over half a million cases and more than 30 major outbreaks reported since it was first isolated in Trinidad and Tobago in 1955 \[[@pntd.0007897.ref004]\]. These figures are likely to be underestimates, caused in part by underreporting due to the similar clinical presentation of other arboviral diseases that co-circulate in the same areas, including dengue virus (DENV), chikungunya virus (CHIKV), Mayaro virus (MAYV), yellow fever virus (YFV) and Zika virus (ZIKV) \[[@pntd.0007897.ref004],[@pntd.0007897.ref005]\]. The primary vector species implicated in urban OROV transmission is the biting midge *Culicoides paraensis*. This is well supported by both experimental and epidemiological data (reviewed in 5). It has been suggested that the widely distributed mosquito species *Culex quinquefasciatus* may contribute to OROV transmission during outbreaks, although efficiency of transmission has been shown experimentally to be lower than that of the primary vector \[[@pntd.0007897.ref001]\]. Cases of Oropouche fever have been reported in Brazil, Peru, Panama, and Trinidad and Tobago \[[@pntd.0007897.ref005]\]. We recently isolated OROV for the first time from a patient in north-western Ecuador \[[@pntd.0007897.ref006]\] suggesting that OROV may be circulating undetected in this region. This led us to further investigate the presence of OROV in an additional 196 febrile patients from the same coastal area of Esmeraldas, Ecuador, sampled in 2016.

Reverse transcription polymerase chain reaction (RT-PCR) is typically used for the detection of viral RNA directly from clinical samples \[[@pntd.0007897.ref007]--[@pntd.0007897.ref010]\]. The rate of detection of OROV RNA in patient plasma during the first five days of illness is reported as 93.3% using a one-step real-time RT-PCR (qRT-PCR) \[[@pntd.0007897.ref007]\]. A disadvantage of RT-PCR is that a conserved target genome sequence is required, making it difficult to detect viral strains that are genetically divergent, reassortant, novel, or of an unexpected virus species. Metagenomic sequencing (untargeted sequencing of all genetic material in a sample) is an attractive alternative to conventional molecular detection methods as it does not require prior knowledge of pathogen genome sequences. For example, an established OROV qRT-PCR \[[@pntd.0007897.ref007]\] was unable to detect OROV in the plasma of an Ecuadorian febrile patient who tested positive using metagenomic sequencing and virus isolation (S segment sequence available at GenBank, accession MF926352.1) \[[@pntd.0007897.ref006]\]. This highlights the potential for misdiagnosis when screening for pathogens that lack a large collection of reference sequences on which to base targeted amplification. Here we report (i) the development of a qRT-PCR with improved sensitivity, (ii) an algorithmically-designed \[[@pntd.0007897.ref016]\] primer set for whole-genome amplification of OROV, and (iii) the prevalence of OROV in the 2016 Esmeraldas patient cohort.

Materials and methods {#sec002}
=====================

Patient samples {#sec003}
---------------

Plasma samples were obtained from patients at Delfina Torres de Concha Hospital, Esmeraldas province, Ecuador, in 2016 (*n* = 196) and 2017 (*n* = 62), along with metadata: patient age, sex, patient location, number of days of fever, and other clinical signs and symptoms.

Ethics statement {#sec004}
----------------

Blood samples were obtained from Delfina Torres de Concha Hospital (Esmeraldas city, Ecuador), from febrile patients who attended the hospital voluntarily and submitted their blood for routine dengue and Zika virus testing. The use of these samples in this project was approved by the Universidad San Francisco de Quito bioethics committee. Samples were anonymised prior to analysis and the patients were not required to fill out informed consent.

RNA extraction and PCR assays {#sec005}
-----------------------------

Plasma samples were spiked with bacteriophage MS2 (1.45 x 10^5^ pfu) as an internal control. RNA was extracted using the QIAamp Viral RNA mini kit (Qiagen) following manufacturer's instructions, substituting the addition of carrier RNA with the same volume of linear polyacrylamide (LPA). A negative extract control (molecular-grade water) was included in each batch of extractions. RNA was screened using Public Health England in-house diagnostic PCR and RT-PCR assays, some of which were adapted from published assays, targeting: DENV \[[@pntd.0007897.ref011]\], CHIKV (in-house), ZIKV \[[@pntd.0007897.ref012]\], YFV \[[@pntd.0007897.ref011]\], MAYV (in-house), *Plasmodium* spp. \[[@pntd.0007897.ref013]\], *Leptospira* spp. (in-house) and *Rickettsia* spp. \[[@pntd.0007897.ref014],[@pntd.0007897.ref015]\].

Metagenomic sequencing {#sec006}
----------------------

DNAse treatment, cDNA preparation, random amplification by SISPA (Sequence-Independent Single Primer Amplification), and Illumina sequencing were performed as described previously \[[@pntd.0007897.ref017]\]. Reads were trimmed to remove adaptors and low-quality bases using trimmomatic (0.3.0) \[[@pntd.0007897.ref018]\] with default parameters, to achieve an average phred score of Q30 across the read.

Taxonomic analysis of reads was undertaken using Centrifuge (Galaxy Version 1.0.3-beta) \[[@pntd.0007897.ref019]\] with index \"Bacteria, Archaea, Viruses, Human\", last updated on 12/06/2016, available at <https://ccb.jhu.edu/software/centrifuge/manual.shtml>, on a local instance of Galaxy \[[@pntd.0007897.ref020]\]. Mapping to OROV genomes was performed using BWA MEM (v0.7.15) \[[@pntd.0007897.ref021]\], using OROV/EC/Esmeraldas/087/2016 (GenBank accessions MF926352.1, MF926353.1, MF926354.1) as references. Quasibam \[[@pntd.0007897.ref022]\] was used to generate consensus sequences, with a 5x coverage cut off. Mapping statistics were generated using SAMtools (v1.4) \[[@pntd.0007897.ref023]\]. Alignment and analysis of nucleotide and protein sequences was performed using the ClustalW method in MegAlign (v14.0.0). Human reads were removed by mapping to the human genome (human_g1k_v37\[1000 genomes\]), non-mapped reads were selected using SAMtools fastq, with flag -F 2. Raw data (stripped of human reads identified via mapping or Centrifuge) is available from the Sequence Read Archive, accession numbers SAMN12241859---SAMN12241881. De novo assembly of non-human reads was performed using SPAdes (v3.8.2) with---meta flag \[[@pntd.0007897.ref024]\]. A BLASTn \[[@pntd.0007897.ref025]\] search was performed on resulting scaffolds larger than 1000 bp, against GenBank (nr/nt) database. Non-human reads were mapped (BWA MEM) to a multifasta file containing sequences from relevant viruses, including at least one representative genome from each PCR screening target (CHIKV, OROV, DENV1, DENV2, DENV3, DENV4, MAYV, YFV, ZIKV), any virus that had appeared during BLAST analysis of *de novo* assembled scaffolds (Hepatovirus A, Rift Valley Fever virus, influenza A virus), and the internal control MS2.

Samples with \>0.02% reads assigned to a virus species by Centrifuge or an assembled scaffold larger than 1500 bp showing homology to a viral sequence using BLASTx were investigated for the presence of that specific virus. A positive virus detection was defined as \>40% genome coverage (1x) generated when mapping to a reference genome.

Virus isolation and quantification {#sec007}
----------------------------------

Vero cells, freely provided by the European Collection of Authenticated Cell Cultures (ECACC; catalogue number 84113001), were inoculated with patient plasma diluted 1:10 in Eagle's minimum essential medium (MEM) to a volume of 1 mL, incubated at 37°C with 5% (v/v) CO~2~ for 96 hours. Cultures were sampled at 24-hour intervals, virus genome replication was determined using OROV qRT-PCR. Virus was harvested, filtered (0.2 μm pore, Sartorius) and stored at -80°C.

Plaque assays were performed on Vero cell monolayers. 250 μl of 10-fold virus dilutions were added to cells and incubated for one hour at 37°C, 5% (v/v) CO~2~. Inoculum was removed, then 3 mL overlay medium (2x MEM, 1% NEAA, 1% antibiotic-antimycotic, (Invitrogen), 2 mM L-glutamine (Fisher Scientific), 10% FBS (Sigma-Aldrich), and 1% Seaplaque agarose (Lonza)) applied and incubated for four days, before fixation and staining using 20% formalin and 2.3% crystal violet, respectively. Plates were air dried and plaques counted to determine virus titre, using the lowest dilution showing \>10 plaques.

Primer alignment {#sec008}
----------------

Primer and probe sequences were aligned using the ClustalW algorithm in the MEGA7 software package, to a set of OROV N gene coding sequences (GenBank) representing the geographic (Brazil, Panama, Peru and Trinidad and Tobago) and temporal diversity of OROV isolates from the 1950s to present day \[[@pntd.0007897.ref026]\].

qRT-PCR limit of detection analysis {#sec009}
-----------------------------------

For OROV qRT-PCR assay optimisation (supporting information), a range of primers were tested ([S1 Text](#pntd.0007897.s001){ref-type="supplementary-material"} and [S1 Table](#pntd.0007897.s003){ref-type="supplementary-material"}) using the Superscript III Platinum One-step Quantitative RT-PCR kit (Invitrogen) in a standard 25 μL reaction, run on an ABI 7500 real-time PCR machine (Applied Biosystems). Optimal conditions were 18 μM of each primer, 12.5 μM probe and standard MgSO~4~ concentration. Cycling conditions: 50°C for 10 minutes, 95°C for 2 minutes, 45 cycles of 95°C for 10 seconds then 60°C for 40 seconds (with quantification analysis of fluorescence performed at the end of each 60°C step) and a final cooling step of 40°C for 30 seconds.

Absolute quantitation of RNA copy number was calculated from a standard curve of target sequence RNA, transcribed using the Megascript kit (Ambion). A 711 bp region of the S segment was amplified from cDNA of OROV/EC/Esmeraldas/087/2016, using primers incorporating a T7 promoter sequence (forward primer sequence 5' GTC AGA GTT CAT TTT CAA CGA TGT ACC ACA ACG G 3', reverse primer sequence 5' GAA ATT AAT ACG ACT CAC TAT AGG G CTC CAC TAT ATG TC 3'). RNA was quantified using the Qubit RNA broad spectrum kit and purity confirmed using the RNA 6000 pico kit on a bioanalyzer (Agilent).

Multiplex tiling RT-PCR primer design {#sec010}
-------------------------------------

The S, M and L segment sequences of OROV/EC/Esmeraldas/087/2016 were concatenated and inputted using default settings to the Primal Scheme \[[@pntd.0007897.ref016]\] webtool (<http://primal.zibraproject.org/>), which implements an algorithm for designing multiplex PCR primers for virus lineages. The designed primer scheme was modified manually to account for segment ends, incorporating 5' and 3' end primers (see supporting information for primer sequences).

RNA from patient sample D-057 and the cell-cultured prototype strain were amplified in two multiplex PCR reactions using the Ecuador OROV primer scheme designed as described above. Primer pools were used at 100 μM. Products were visualised by gel electrophoresis and quantified using Qubit fluorometric quantitation. These were sequenced on a MinION (Oxford Nanopore, UK) and data processed as previously described \[[@pntd.0007897.ref016]\].

Results {#sec011}
=======

Development of an OROV qRT-PCR {#sec012}
------------------------------

An existing S segment assay \[[@pntd.0007897.ref007]\] failed to detect OROV RNA in an Ecuadorian clinical sample that tested positive by both metagenomic sequencing and virus isolation ([S1 Fig](#pntd.0007897.s011){ref-type="supplementary-material"}) \[[@pntd.0007897.ref006]\]. The reverse primer (OROV R) \[[@pntd.0007897.ref007]\] had two mismatches to the novel OROV/EC/Esmeraldas/087/2016 sequence. We attempted to improve sensitivity by analysing primer and probe suitability. Two new reverse primers were designed; one with mismatches corrected (Ec R) and one at a new site (Ec2 R) ([S1 Table](#pntd.0007897.s003){ref-type="supplementary-material"}), based on an alignment of all publicly available OROV S segment sequences. Testing was performed against both OROV/EC/Esmeraldas/087/2016 and the 1955 prototype Trinidad and Tobago isolate from a distinct lineage (GenBank KP026181.1). The original reverse primer showed reduced sensitivity for the Ecuadorian strain compared with the prototype strain, which were detected to the 10^−4^ and 10^−6^ dilutions respectively ([Fig 1](#pntd.0007897.g001){ref-type="fig"}). Primer Ec R showed improved sensitivity for the Ecuadorian strain but reduced sensitivity for the prototype strain, with detection possible to the 10^−7^ and 10^−3^ dilutions respectively ([Fig 1](#pntd.0007897.g001){ref-type="fig"}). Ec2 R improved sensitivity by three logs for the Ecuadorian strain and by one log for the prototype strain, compared with the original reverse primer ([Fig 1](#pntd.0007897.g001){ref-type="fig"}). The final assay using Ec2 R underwent validation. The standard curve demonstrated a linear relationship between mean Cq value and log RNA copy number, the absolute limit of detection of the qRT-PCR assay was 10 copies of OROV RNA at a mean Cq value of 38.25 (95% CI 37.8 to 38.7, [S2 Fig](#pntd.0007897.s012){ref-type="supplementary-material"}). No cross-reactivity was observed in exclusivity testing against 23 virus species ([S2 Table](#pntd.0007897.s004){ref-type="supplementary-material"}) within the *Alphavirus*, *Flavivirus*, *Phlebovirus*, *Orthobunyavirus*, *Nairovirus* and *Mammarenavirus* genera. Primer and probe sequences were aligned with all publicly available OROV N gene sequences (*n* = 149) to identify mismatches that may reduce sensitivity for certain strains. Of the 149 sequences, 19 had mismatch(es) to the forward primer, 21 sequences showed a mismatch to the probe, and 26 had mismatch(es) to the original reverse primer OROV R, six of which were mismatches at two positions ([S3 Table](#pntd.0007897.s005){ref-type="supplementary-material"}). In contrast, no sequence had more than one mismatch to the new reverse primer Ec2 R, however, the number of sequences with a single mismatch was higher (*n* = 41).

![Sensitivity analysis of three reverse primers used in the qRT-PCR assay.\
Cq values are shown for ten-fold serial dilutions of OROV RNA, either from the prototype strain (GenBank KP026181.1), or the Ecuadorian strain OROV/EC/Esmeraldas/087/2016 (GenBank MF926352.1). Three separate experiments were performed, from which the means (plotted as data points) and standard deviations (indicated by error bars) were calculated. Reverse primer sequences (5'--3') are given in the embedded table.](pntd.0007897.g001){#pntd.0007897.g001}

Pathogen identification in febrile patients using PCR {#sec013}
-----------------------------------------------------

We initially used nine PCR or RT-PCR assays to screen serum from Ecuadorian patients with undifferentiated febrile illness for pathogens previously reported from the country. Following our previous metagenomic sequencing based identification of OROV in one of these samples \[[@pntd.0007897.ref006]\], and improvement of the OROV qRT-PCR, we re-screened all patient samples for OROV. PCR screening identified positive cases (Cq value \<35) of ZIKV (prevalence 11.2%, *n* = 22), DENV (prevalence 2.0%, *n* = 4), OROV (prevalence 3.1%, *n* = 6), and *Leptospira* spp. (prevalence 0.51%, *n* = 1) ([Fig 2](#pntd.0007897.g002){ref-type="fig"}). In addition, a number of potentially positive cases (Cq value 35--39.9) were identified (ZIKV *n* = 15, DENV *n* = 3, CHIKV *n* = 2. and *Leptospira* spp. *n* = 1, [Fig 2](#pntd.0007897.g002){ref-type="fig"}). Cq values in this upper range require additional testing to confirm positive status (this was performed for the Cq \>35 OROV sample, but not for the other pathogens). No cases of MAYV, YFV, *Plasmodium* spp. or *Rickettsia* spp. were identified. 147 samples were negative for all pathogens tested. All samples were qRT-PCR-positive for internal control MS2.

![Cq values from 49 pathogen positive or potentially positive plasma samples, from a cohort of 196 screened by qRT-PCR.\
Samples with a Cq value of 35--39.9 should be considered potentially positive because (except for the OROV sample) confirmatory tests were not performed. Lepto = *Leptospira* spp.](pntd.0007897.g002){#pntd.0007897.g002}

Follow up screening of febrile patient samples from 2017 {#sec014}
--------------------------------------------------------

Sixty-two samples from febrile patients from Esmeraldas, taken in 2017, were tested for OROV, CHIKV, DENV, MAYV, YFV, ZIKV and *Rickettsia* spp. by PCR and RT-PCR. All samples were negative for all pathogens and positive for internal control MS2.

Pathogen confirmation and genome characterisation using metagenomic sequencing {#sec015}
------------------------------------------------------------------------------

All OROV qRT-PCR-positive samples were also OROV-positive by metagenomic sequencing, demonstrating that detection is possible from patient plasma samples with OROV RNA concentrations as low as 9.62e+3 genome copies/mL ([S4 Table](#pntd.0007897.s006){ref-type="supplementary-material"}). Mapping reads to reference sequence OROV/EC/Esmeraldas/087/2016 resulted in genome coverage ranging from 68--99% ([Fig 3](#pntd.0007897.g003){ref-type="fig"}). The proportion of OROV-specific reads does not appear to be particularly strongly correlated with Cq value, differences in the background level of non-viral RNA (in particular from the host) could account for this. It was still somewhat indicative of OROV genome coverage generated ([Fig 3](#pntd.0007897.g003){ref-type="fig"}), with coverage generally decreasing as Cq increases. OROV reads were not detected in any of the 17 pathogen PCR-negative samples also tested. Hepatovirus A (HAV, formerly hepatitis A virus) was identified in one sample, with 1,894 reads providing 40% genome coverage ([Table 1](#pntd.0007897.t001){ref-type="table"}). Reads specific to internal control MS2 were identified in all PCR-negative samples.

![OROV genome coverage generated from six OROV-positive patient plasma samples, using a metagenomic sequencing approach.\
Reads were mapped to reference sequences OROV/EC/Esmeraldas/087/2016 (GenBank accessions MF926352.1- MF926354.1). **Panel A:** OROV genome segment (S, M, L) coverage (%). qRT-PCR Cq value is given at the top of each plot. Coverage is defined as a minimum of 5 reads at any given position. **Panel B:** OROV genome coverage shown as the number of reads at each genomic position. Plots are separated by genome segment (S, M, L). Red dashed line indicates 5x coverage.](pntd.0007897.g003){#pntd.0007897.g003}

10.1371/journal.pntd.0007897.t001

###### Viruses identified from 23 patient plasma samples by metagenomic sequencing, 17 of which were negative for all pathogens tested for by RT-PCR, including one sample (D-087) in which OROV was initially detecting by metagenomic sequencing.

The remaining five samples (D-057, D-155, D-171, D-206 and D-210) were initially shown to be positive for OROV using the qRT-PCR assay described in this study. The cut-off value used was ≥40% genome coverage (from mapping reads to reference genome).

![](pntd.0007897.t001){#pntd.0007897.t001g}

  Sample ID                                    Virus identified   \% of total reads assigned by Centrifuge   Reads assigned by Centrifuge   Reads mapped to reference sequence   1x genome coverage (%)   Mapping reference (accession number)
  -------------------------------------------- ------------------ ------------------------------------------ ------------------------------ ------------------------------------ ------------------------ --------------------------------------
  D-005                                        HAV                0.02                                       478                            1,894                                40                       LC049339.1
  D-057                                        OROV               7.42                                       143,925                        870,960                              99                       MF926352.1--54.1
  D-087                                        OROV               0.70                                       5,084                          9,972                                80                       MF926352.1--54.1
  D-155[\*](#t001fn001){ref-type="table-fn"}   OROV               1.97                                       66,686                         24,274                               90                       MF926352.1--54.1
  D-171[\*](#t001fn001){ref-type="table-fn"}   OROV               3.13                                       94,248                         145,146                              95                       MF926352.1--54.1
  D-206                                        OROV               0.63                                       25,050                         277,019                              68                       MF926352.1--54.1
  D-210                                        OROV               4.15                                       78,747                         733,986                              92                       MF926352.1--54.1

\*Data are from two separate sequencing runs combined.

Confirmation of OROV infection in qRT-PCR-positive patients by virus isolation {#sec016}
------------------------------------------------------------------------------

OROV was successfully cultured in Vero cells from all five OROV-positive patient plasma samples (virus was isolated from the initial patient D-087 as previously reported \[[@pntd.0007897.ref006]\]). S segment copy numbers for all samples increased by at least 5 logs to approximately 1.00e+12 copies/mL at 72 hours post-infection ([S3 Fig](#pntd.0007897.s013){ref-type="supplementary-material"}), demonstrating that OROV was replicating. Confirmation of the presence of infectious virus was undertaken by plaque assay using P1 supernatant from the representative isolate OROV/EC/Esmeraldas/087/2016 from patient D-087, which formed plaques on Vero cells indicating a titre of 1.56e+7 pfu/mL. A subsequent passage (P2) on Vero cells, also assessed by plaque assay, further confirmed the presence of infectious virus.

RNA from cultured viral supernatant (one passage in Vero cells) underwent metagenomic sequencing and the resulting reads were mapped to reference genome OROV/EC/Esmeraldas/087/2016. Complete genomes were generated from all isolates and are available on GenBank, accession numbers MK506818---MK506832.

The genomes were 99.7--100% identical to one another in the S segment and 99.9--100% identical in the M and L segments. Single nucleotide polymorphisms (SNPs) were observed at 33 positions throughout the genome, all of which occurred in coding regions ([S5 Table](#pntd.0007897.s007){ref-type="supplementary-material"}). Alignment of protein sequences showed that the N protein was 100% identical between isolates, whilst the NSs protein had a single amino acid substitution in isolate D-206. Isolate D-210 had two amino acid substitutions in the M protein, whilst three isolates (D-057, D-155 and D-206) had one substitution in this protein. Two isolates (D-155 and D-210) had a single amino acid substitution in the L protein ([S6 Table](#pntd.0007897.s008){ref-type="supplementary-material"}). Of the eight substitutions seen, five constitute a reactive (R) group change (three on the M segment and two on the L segment) and therefore may influence the structure or function of the protein.

The genome sequences from the patient and cultured sequences were compared to identify SNPs incurred during passage. The number of SNPs per genome ranged from one (sample D-057) to 15 (sample D-155) ([S7 Table](#pntd.0007897.s009){ref-type="supplementary-material"}). The majority of changes were from a mixed population (mixed defined as no one base occupying \>80% of reads at a position) in the patient, to either a different mixed population, or a majority population (majority defined as one base occupying \>80% reads at a position) in the cultured isolate ([S8 Table](#pntd.0007897.s010){ref-type="supplementary-material"}). Changes from a majority population in the patient were less common, seen at two (samples D-171 and D-210) to five (sample D-087) positions, with sample D-057 showing no changes of this type ([S8 Table](#pntd.0007897.s010){ref-type="supplementary-material"}). Only one of the 49 positions with polymorphisms between patient and cultured sequences was conserved between isolates (M segment position 59, [S8 Table](#pntd.0007897.s010){ref-type="supplementary-material"}).

Development of an OROV multiplex tiling RT-PCR primer scheme {#sec017}
------------------------------------------------------------

Samples with lower levels of viral RNA often present challenges in generating complete genome sequences using the metagenomic sequencing approach ([Table 1](#pntd.0007897.t001){ref-type="table"} and [Fig 3](#pntd.0007897.g003){ref-type="fig"}). To address this problem, a set of targeted genome amplification primers was designed using the algorithmic method described by Quick *et al*. \[[@pntd.0007897.ref016]\] ([S2 Text](#pntd.0007897.s002){ref-type="supplementary-material"}). Using a cut-off of 20x read depth, \>99% coverage of all three Ecuadorian OROV genome segments was obtained (average coverage of 7,075x, 9,894x and 7,381x for the S, M and L segments, respectively) directly from clinical sample D-057 ([Fig 4](#pntd.0007897.g004){ref-type="fig"}). For the prototype strain, 98% of the S segment (average coverage = 126,860x), 93% of the M segment (average coverage = 119x) and 92% of the L segment (average coverage = 189x) were obtained, despite its sequence divergence from the Ecuadorian strains.

![Genome coverage of two OROV strains (Ecuadorian strain OROV/EC/Esmeraldas/087/2016 Genbank MF926352.1---MF926354.1, and prototype strain Genbank KP026179.1---KP026181.1), sequenced using a MinION (Oxford Nanopore), from multiplex tiling RT-PCR amplicons.\
Plots are separated by genome segment (S, M, L). Red dashed line indicates 20x coverage.](pntd.0007897.g004){#pntd.0007897.g004}

Discussion {#sec018}
==========

Using metagenomic sequencing followed by screening using an optimised qRT-PCR, we have detected a cluster of six OROV cases from patients local to Esmeraldas, Ecuador, providing further evidence that OROV may be causing an unrecognised burden of human disease in previously unreported areas.

Some of these cases were not detected by the previously published assay due to a primer mismatch with the Ecuadorian genomes, which was identified in the metagenomic sequencing data. This discovery highlights the problems in developing amplification-based detection assays for pathogens with limited numbers of sequenced genomes, and the benefits offered by unbiased sequencing technologies. Although the cost associated with metagenomic sequencing may be prohibitive for frontline diagnosis in developing countries, it can be used in prospective screening studies to identify potential issues with qRT-PCR assays and allow for alterations to increase inclusivity, as reported here. We developed a new reverse primer for the previously published assay that improves sensitivity for both the Ecuadorian strain (capable of detecting 10 copies of target RNA) and the genetically divergent prototype strain. Other OROV strains were not available to validate against, however an alignment of all publicly available strains showed that the majority of sequences are homologous to the primer/probe sequences. The qRT-PCR amplifies a region in the S segment, the target sequence of which is shared by a number of reassortant orthobunyaviruses, including Iquitos virus, which is known to circulate in neighbouring Peru and can cause Oropouche fever \[[@pntd.0007897.ref027]\]. This modified assay also has the potential to detect reassortant orthobunyaviruses containing the OROV S segment. An algorithmically-designed multiplex primer set was developed that can amplify the majority of the genome from both the Ecuadorian and prototype strains and may be a useful tool for sequencing OROV genomes from clinical samples with low viral titres.

Virus identification in the Ecuadorian cohort was undertaken initially using PCR. In addition to OROV, screening identified the presence of ZIKV, DENV, *Leptospira* spp. and possibly CHIKV nucleotide sequences. These pathogens are known to circulate in Ecuador \[[@pntd.0007897.ref028]--[@pntd.0007897.ref030]\]; ZIKV in particular was widespread in the Americas (including Ecuador) at the time of sampling \[[@pntd.0007897.ref031]\], so the identification of a relatively large number of ZIKV cases (*n* = 22 positive, *n* = 15 potentially positive) was not unexpected. Cq values of 35--39.9 were observed for multiple samples across all identified pathogens. Samples with values in this range require confirmatory testing to be certain of the presence of the pathogen.

Metagenomic sequencing of 17 PCR-negative samples identified HAV sequence in one patient; no other viruses were conclusively identified. Ecuador is considered an 'intermediate endemicity' country for HAV \[[@pntd.0007897.ref032]\] and therefore identification of this virus is not unexpected. The lack of viral sequences from the majority of the patient samples could be explained by a number of factors including clearance of virus from the blood by the time of sampling, or fever caused by non-infectious disease. Metagenomic sequencing successfully identified OROV in all OROV qRT-PCR-positive patients, with good genome coverage (68--99%), suggesting that this method is effective for both detection and characterisation of OROV genomes from clinical samples. Sequencing of one sample (D-206) produced M and L segment-specific reads that mapped to the reference sequence, however only two reads mapping to the S segment. The absence of S segment signal here is simply due to the stochastic nature of the metagenomic sequencing method, which is exacerbated for smaller fragments. The S segment is both detected by qRT-PCR (at a Cq value of 30.9, the second highest value of all six OROV-positive patients) and is present in the sequencing of the virus directly cultured from this sample.

The generation of complete viral genomes using metagenomic sequencing or a multiplex tiling RT-PCR (as opposed to the small fragments generated using conventional qRT-PCR) enables more detailed and accurate molecular epidemiological analyses \[[@pntd.0007897.ref033]\]. Initial phylogenetic analysis of S, M and L segments showed that the five additional Ecuadorian genomes cluster in a monophyletic group with our previously reported Ecuadorian strain, suggesting the possibility of local transmission within Esmeraldas. An investigation of potential OROV vector species in Esmeraldas would be highly informative. The group is most closely related to strain TVP-19256/IQE-7894 from Peru, 2008 (GenBank KP795084.1---KP795086.1). A comprehensive phylogenetic analysis of OROV in South America, including the Ecuadorian genomes, has been undertaken \[[@pntd.0007897.ref026]\].

It is well-documented that mutations occur during passaging *in vitro* \[[@pntd.0007897.ref034]\]. Our study generated complete genome sequences from viruses that had undergone one passage in Vero cells. The single passage was necessary to amplify virus and generate complete genome sequences, however, passaging was limited to minimise the number of mutations between patient and cultured viral genomes. A number of positions in the OROV patient genomes showed a mixed population of variants, which progressed to a majority population in the cultured genome. Majority-majority changes were rare and only one of the 49 SNPs observed between patient and cultured genomes was shared in two individual strains.

No cases of OROV were detected during follow-up qRT-PCR screening of 62 febrile patients from Esmeraldas, 2017. Previous outbreaks of Oropouche fever have been episodic and self-limited in nature \[[@pntd.0007897.ref004]\]; the six cases identified from 2016 could represent a single outbreak that ended that year. Alternatively, if OROV transmission did occur in Esmeraldas in 2017, the lack of detection could be related to the limited sample size of the cohort. A larger-scale study is necessary to determine the prevalence and distribution of OROV in the Ecuadorian population.

OROV infection should be considered when diagnosing Ecuadorian patients with febrile illness. We hope that the molecular tools developed in this study will be useful for laboratories performing viral diagnostics and surveillance in the Americas. Very little is known about the dynamics of OROV in Ecuador or endemicity in neighbouring regions; the detection of OROV in multiple febrile patients warrants further investigation into its prevalence, associated vectors, and transmission.
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###### The workflow that led to the identification and isolation of OROV from six febrile Ecuadorian patients.
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###### Absolute quantitation was performed from a standard curve generated from a ten-fold serial dilution of a synthetic OROV RNA standard.

Each data point is the mean Cq value from three separate experiments. Error bars indicate standard deviation. R^2^ correlation coefficient = 0.9978.
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###### OROV genome copies increase over 96 hours in Vero cells, demonstrating OROV genome replication in five independent OROV cultures from OROV-positive patient plasma.
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19 Sep 2019

Dear Miss Wise:

Thank you very much for submitting your manuscript \"Oropouche virus cases identified in Ecuador using an optimised qRT-PCR informed by metagenomic sequencing\" (PNTD-D-19-01189) for review by PLOS Neglected Tropical Diseases. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed (uploaded as a \"Revised Article with Changes Highlighted\" file); the other a clean version (uploaded as the article file).

\(3\) If available, a striking still image (a new image if one is available or an existing one from within your manuscript). If your manuscript is accepted for publication, this image may be featured on our website. Images should ideally be high resolution, eye-catching, single panel images; where one is available, please use \'add file\' at the time of resubmission and select \'striking image\' as the file type.

Please provide a short caption, including credits, uploaded as a separate \"Other\" file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plosntds/s/content-license> (NOTE: we cannot publish copyrighted images).

\(4\) Appropriate Figure Files

Please remove all name and figure \# text from your figure files upon submitting your revision. Please also take this time to check that your figures are of high resolution, which will improve both the editorial review process and help expedite your manuscript\'s publication should it be accepted. Please note that figures must have been originally created at 300dpi or higher. Do not manually increase the resolution of your files. For instructions on how to properly obtain high quality images, please review our Figure Guidelines, with examples at: <http://journals.plos.org/plosntds/s/figures>

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We hope to receive your revised manuscript by Nov 18 2019 11:59PM. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

To submit your revised files, please log in to <https://www.editorialmanager.com/pntd/>

If you have any questions or concerns while you make these revisions, please let us know.

Sincerely,

Mariangela Bonizzoni

Associate Editor

PLOS Neglected Tropical Diseases

A. Desiree LaBeaud

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: (No Response)

Reviewer \#2: All methods are adequate for the hypothesis to be tested, the sample size is sufficient and the statistical analysis support well the conclusions.

Reviewer \#3: The objectives of the study are well defined and clearly articulated. The methodology is well written, and the large sample size used here is a strong point of this manuscript. There are some areas which should be expanded with greater details given, on order to aid the reader.

Specific comments:

• RNA extraction and PCR assays: Are the in house PHE assays published? If so, they should be referenced here.

• LOD analysis: what was the rationale behind using a 711bp fragment of S segment, rather than the entire S genome for the in vitro transcript control material?

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: (No Response)

Reviewer \#2: The results presented here matched well the analysis plan. All results were clear and well presented. The figures and all supporting material are of good quality.

Reviewer \#3: The results section is for the most part clearly written, easy to follow, and the data are presented in a logical and methodical way. I think it would be beneficial to include more details in all the figure and table legends as they are rather sparse - such as (where appropriate): GenBank numbers, sample IDs, number of samples per group.

One section I think could be improved on is the confirmation of infectious OROV in the positive plasma. Here, the authors describe a method where they monitored S genome levels over time in vitro, and used increasing viral RNA levels as proof of viral isolation. While this observation may be true, I feel this would be a much more convincing statement if there was more direct evidence that OROV was actively replicating and producing new virions in vitro. Ultimately, a P2 passage onto Vero cell would be the gold standard here, but evidence of CPE (OROV in Vero cells causes extensive cell death) or protein production (e.g. IFA analysis) should be reported. One reason I think it's very important to confirm active and productive viral replication is that the S genome copies/ml determined by qRT-PCR reported here are very high. At this level (even though it is difficult to equate RNA copy numbers to actual virion numbers) I would think the titer would be capable of destroying a Vero monolayer in \~24 hours, whereas data presented here would suggest at least some cell survival up to 96 hpi?

Specific comments:

• Development: There are several "reduced sensitivity" and "improved sensitivity" statements in this section, and some are quantified (i.e. 3 logs) and some are not. If possible, all variations in sensitivity should be consistently quantified by some measure.

• Development: How many publicly available OROV N gene sequences are there (n=?). This should be stated.

• Fig 2: These data should be performed/presented in at least triplicate, and analyzed using a trend line to determine efficiency and sensitivity difference between both viral strains and assays (similar to analysis in Fig S1).

• Was there a specific reason why plasma samples from 2016 and 2017 were sampled separately? If so, this should be stated in the text.

• Confirmation of infectious OROV: Should say "S genome copies" rather than "genome copies". The number of reactive group substitutions (of the 5 total) on each segment should be stated.

• Supplementary Table 6: I think it would be useful to the reader to know what these SNPs were rather than just the number per segment.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: (No Response)

Reviewer \#2: The conclusion support well the data presented and I did not see any limitation of the study. All data are well discussed and the paper is a good source of information about the history of the Oropouche virus. This paper is a great public relevance as it highlights the problems of OROV in Ecuador and Latin America.

Reviewer \#3: The discussion is well written, and both expands on the results and brings in valid discussion points as to the relevance of these data.

One specific comment that isn't explained in the results, and perhaps should be touched upon in the discussion in sample D-206. This sample was PCR positive, had a large number of reads mapping to the reference sequence, but yet no S genome coverage was obtainable using the NGS? Do the authors have any explanation for this? NGS results like this would suggest a reassortant (although an S-only bunyavirus reassortants would be very rare), but the qRT-PCR seems to contradict this. Even if ultimately this result was due to an assay failure, this should at least be brought up in the discussion rather than left unexplained.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: I do not have major editorial suggestions, only to encourage the authors to double check all references and format of the journal.

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: In this study the authors develop a new diagnostic tool for Oropouche virus, a neglected arbovirus circulating in South America. The optimization and validation of qRT-PCR was performed basing on a metagenomic data obtained by sequencing human plasma sample from Ecuador. The presented qRT-PCR was able to identify OROV in samples previously tested as negative. The results presented will improve the capacity to detect of OROV in endemic regions. The paper is well written, and all data are available. All my concerns are minor.

1\) I would like to read some more information in the introduction about the vectors involve in the transmission cycle of OROV, also considering that the authors highlight the need of more vector competence studies in discussion.

2\) Figure 1 does not seem to add much to the paper as it's a technical type figure. i suggest to delete it.

3\) Lines 100-105: in this chapter of MM the authors don't report the Genbank number of the sequence used. I try to find them in the cited paper but I was not able to find the data. I suggest to clarify this point.

4\) Considering the main object of this paper, I would like to see the primer sequences in the main text and not only in a table in supplementary information.

5\) Lines 313-318: the authors have report positive Cq values of 35-40 (table 3) but these data require confirmatory test. If they don't provide the confirmation of these results I would be conservative and indicate the samples as possible positive.

Reviewer \#2: I really enjoyed reading the paper and the methodologies used to detect OROV in Ecuador. I congratulate the authors in devising a new set of primers that detect variants of OROV.

I encourage the publication of this paper.

Reviewer \#3: In the manuscript "Oropouche virus cases identified in Ecuador using an optimized qRT-PCR informed by metagenomic sequencing", Wise et al. describe the use of metagenomic sequencing to aid in the design of PCR assays to detect OROV, and perform analysis on historical samples from patients with undiagnosed fevers to investigate OROV in an endemic area. The experiments are well thought out, the paper is well written, and the data presented in a clear and concise manner.

My one suggestion to increase the strength of this manuscript would be to perform further work on the experiments investigating OROV isolation from the patient plasma samples. This data would benefit from extra experimental work to confirm presence of replicating OROV.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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31 Oct 2019

Dear Miss Wise,

We are pleased to inform you that your manuscript, \"Oropouche virus cases identified in Ecuador using an optimised qRT-PCR informed by metagenomic sequencing\", has been editorially accepted for publication at PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please note: your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\* Copyediting and Author Proofs: To ensure prompt publication, your manuscript will NOT be subject to detailed copyediting and you will NOT receive a typeset proof for review. The corresponding author will have one final opportunity to correct any errors when sent the requests mentioned above. Please review this version of your manuscript for any errors.

\* If you or your institution will be preparing press materials for this manuscript, please inform our press team in advance at <plosntds@plos.org>. If you need to know your paper\'s publication date for media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. PLOS NTDs may choose to issue a press release for your article. If there is anything that the journal should know, please get in touch.

\*Now that your manuscript has been provisionally accepted, please log into EM and update your profile. Go to <http://www.editorialmanager.com/pntd>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

\*Note to LaTeX users only - Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines \[<http://www.plosntds.org/static/latexGuidelines.action>\] in the meantime.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Mariangela Bonizzoni

Associate Editor

PLOS Neglected Tropical Diseases

A. Desiree LaBeaud

Deputy Editor

PLOS Neglected Tropical Diseases
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9 Jan 2020

Dear Miss Wise,

We are delighted to inform you that your manuscript, \"Oropouche virus cases identified in Ecuador using an optimised qRT-PCR informed by metagenomic sequencing,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Serap Aksoy

Editor-in-Chief

PLOS Neglected Tropical Diseases

Shaden Kamhawi

Editor-in-Chief

PLOS Neglected Tropical Diseases

[^1]: The authors have declared that no competing interests exist.
